The World Health Organization has issued new guidelines recommending universal newborn pulse oximetry screening for critical congenital heart disease, a low-cost intervention estimated to prevent 250,000 neonatal deaths per year globally.
The World Health Organization (WHO) has published updated neonatal care guidelines formally recommending universal pulse oximetry screening for critical congenital heart disease (CCHD) for all newborns within 24-48 hours of birth.
Congenital heart disease affects approximately 1 in 100 live births globally — around 1.35 million babies annually — and remains the leading cause of infant mortality from birth defects. Up to 30% of CCHD cases are not detected by physical examination alone.
The Screening Protocol
The recommended protocol involves measuring SpO2 in the right hand and either foot using a pulse oximeter. A reading below 95% or a difference >3% between sites triggers referral for echocardiography.
- Sensitivity: 76% for CCHD, 92% for critical lesions
- Specificity: 99.9%
- Cost: <$1 per baby in low-resource settings
- Implementation feasible without echocardiography on-site
The WHO estimates universal implementation of this protocol across LMICs could prevent 250,000 neonatal deaths and 180,000 cases of severe neurodevelopmental impairment annually.
Leading pulse oximetry manufacturers including Masimo, Nonin and Nellcor have committed to supplying subsidised devices to 45 low-income countries under the WHO Essential Equipment programme.